ST. LOUIS — Bayer has won the first Roundup trial to reach a jury since the United States Supreme Court narrowed the legal claims available to plaintiffs in June 2026, a result the company hopes will reshape the thousands of cancer lawsuits still pending against it. A St. Louis jury unanimously ruled for Bayer-owned Monsanto in a case brought by three women who claimed that regular use of the weedkiller Roundup caused them to develop non-Hodgkin lymphoma, a type of blood cancer. The verdict, reported on October 30, 2026, rejected the claims that were put to the jury, which concerned whether the product was defectively designed, whether the company committed fraud, and whether it was negligent in selling it.
The case was closely watched because it was the first test of whether Roundup lawsuits can still succeed after the Supreme Court’s decision in Monsanto v. Durnell. That ruling did not decide whether glyphosate, Roundup’s active ingredient, causes cancer, and it did not grant Bayer blanket immunity from every kind of claim. What it did was close off one major avenue of attack: state-law claims that a manufacturer failed to warn consumers by leaving a cancer warning off a label that the federal Environmental Protection Agency had approved without one. The St. Louis trial therefore became a test of the theories that remained open after that door closed, and on those theories, the jury sided with the defence on every question it was asked.
What the St. Louis jury decided
The plaintiffs in the case were Theresa Aretino, Cynthia Fernandez and Betty Larkin, who sued Monsanto in St. Louis in 2020. They said they used Roundup regularly and later developed non-Hodgkin lymphoma, and they argued that the product was defectively designed and unreasonably dangerous and that Bayer was negligent in selling it. Their lawyers asked the jury to hold Monsanto liable on those grounds. The jury disagreed, returning a unanimous defence verdict on the claims submitted to it.
It is important to be precise about what the verdict did and did not decide. The jury decided the claims of these three plaintiffs on the evidence presented at this trial. It did not issue a general scientific ruling that glyphosate is safe or unsafe, and a single trial verdict does not settle the scientific dispute over glyphosate that has run for more than a decade. Nor did the verdict resolve the tens of thousands of other claims still pending in state and federal courts, each of which turns on its own facts, exposure history and legal theories. What the verdict did do was give Bayer its first courtroom win in the post-Durnell landscape, and both sides will now study it for clues about how future juries may respond to the surviving claims.
Bayer’s United States general counsel and global head of litigation, Bill Dodero, said the verdict should send a strong signal that plaintiffs who wish to pursue claims in the court system following the Supreme Court ruling will face significant challenges. That framing is, of course, the company’s own reading of the result, and plaintiffs’ lawyers may read it differently, emphasising that each trial depends on its own record. Attorneys for Aretino, Fernandez and Larkin did not immediately respond to a request for comment late on the day of the verdict, according to Reuters reporting of the trial, so the plaintiffs’ side has not yet publicly set out its next steps in this case, including whether it will appeal.
How the Monsanto v. Durnell ruling changed the case
To understand why this trial mattered, it helps to retrace the Supreme Court’s June 25, 2026 decision in Monsanto v. Durnell. The case began when John Durnell sued Monsanto in Missouri state court, claiming that about two decades of Roundup use caused his non-Hodgkin lymphoma and that the product’s label should have carried a cancer warning. A jury agreed with him and awarded more than 1 million dollars on the failure-to-warn theory. Monsanto argued that the claim was preempted by the Federal Insecticide, Fungicide, and Rodenticide Act, known as FIFRA, because federal law bars states from imposing pesticide labelling requirements that are in addition to or different from the federal requirements.
In a 7-2 decision written by Justice Brett Kavanaugh, the Supreme Court agreed. The majority reasoned that the Environmental Protection Agency has repeatedly registered Roundup and approved its label without a cancer warning, because the agency has concluded that glyphosate is not likely to cause cancer, and that federal regulations require manufacturers to use the EPA-approved label unless the agency approves or requires a different one. On that view, a state-law claim demanding a cancer warning would impose a labelling requirement different from the federal one, and FIFRA’s preemption clause therefore blocks it. Justices Ketanji Brown Jackson and Neil Gorsuch dissented, arguing that the failure-to-warn claim was equivalent to, rather than different from, federal requirements and that the majority’s reading left Durnell without a remedy.
The practical effect of Durnell was to remove the failure-to-warn theory that had driven many earlier Roundup verdicts and settlements from the table in state court, while leaving other theories to be tested. That distinction shaped the St. Louis trial directly: with failure-to-warn claims preempted, the plaintiffs’ case had to stand on design-defect, fraud and negligence arguments instead. Those arguments ask different questions from a warning claim. Rather than focusing only on what the label said, they ask whether the product itself was unreasonably dangerous as designed, whether the company misled consumers or regulators about its safety, and whether it acted carelessly in bringing the product to market. The St. Louis jury’s answer to those questions was no, at least on the evidence it heard.
The claims the jury heard, and the ones it did not
Design-defect claims are often the hardest for plaintiffs to win in a case involving a widely used product, because they require showing not just that a product carries some risk but that its design was unreasonably dangerous when weighed against its usefulness and against safer alternatives that were available. Bayer’s position throughout the Roundup litigation has been that decades of studies show glyphosate is safe when used as directed and does not cause cancer, a position the company restated after the St. Louis verdict. Plaintiffs’ lawyers, by contrast, have pointed to the International Agency for Research on Cancer’s classification and to studies they say link heavy glyphosate exposure to non-Hodgkin lymphoma, arguing that the company knew or should have known of the risk and failed to act on it.
Fraud claims add another layer, because they typically require showing that the company made false statements or concealed material facts with the intent that consumers would rely on them. Negligence claims ask whether the company exercised reasonable care in designing, testing and marketing the product. Both theories turn heavily on internal documents, expert testimony and the credibility of witnesses about what the company knew and when it knew it. A jury that rejects all three theories, as the St. Louis jury did, is therefore saying something broader than that a label was adequate: it is saying that, on this record, the plaintiffs did not prove the product was defectively designed, that the company defrauded them, or that it acted negligently. That breadth is why Bayer is presenting the verdict as a signal for the litigation as a whole, even though future juries will hear different records.
What the Bayer Roundup trial verdict means for 65,000 pending claims
The stakes beyond this single courtroom are enormous. Bayer faces around 65,000 claims in United States state and federal courts from people who say they developed cancer after using the weedkiller at home or at work, according to reporting on the St. Louis verdict. The company has already spent more than 10 billion dollars settling thousands of Roundup cases since it acquired Monsanto, the developer of Roundup, in 2018. That history explains why a single post-Durnell verdict attracts so much attention: if plaintiffs can still win on design-defect, fraud or negligence theories, the litigation continues largely as before, albeit on narrower grounds; if they cannot, Bayer’s leverage in settlement talks and in future trials grows considerably.
Neither outcome follows automatically from one verdict. Jury trials are fact-specific, and a different panel hearing different exposure histories, experts and documents could reach a different conclusion, while defence lawyers will now cite a unanimous post-Durnell defence verdict when arguing the remaining theories are difficult to prove. The honest reading of the St. Louis result is therefore modest but real: it is one data point, and a favourable one for Bayer, in a litigation that will need many more before either side can claim the overall direction is settled.
The proposed $7.25 billion settlement still under review
Running alongside the individual trials is a separate effort to resolve a large share of the pending cases all at once. Bayer is seeking to settle tens of thousands of other Roundup lawsuits through a proposed 7.25 billion dollar settlement, which is currently under review by a Missouri state court judge in St. Louis. It is essential to describe that proposal accurately: it is proposed and under review, not approved, and until a judge acts, no claimant can be said to have received money under it or to be bound by its terms. News reports sometimes compress this stage into shorthand that sounds final, but a proposal under judicial review can still be modified, conditioned or rejected.
The three women in the St. Louis trial were not participating in the proposed settlement, which is why their case proceeded to a jury verdict while the settlement proposal awaited a ruling in a separate court. That separation matters for understanding the litigation’s structure. Settlements and trials are not alternatives that cancel each other out; they run in parallel, with some claimants choosing to pursue individual trials and others choosing to join a collective resolution if one is approved. If the Missouri judge approves the proposed settlement, it could resolve a large portion of the pending claims, though the details of eligibility, payment levels and any opt-out rights would depend on the final approved terms. If the judge rejects or alters it, the parties would return to negotiating, litigating or both.
Glyphosate and cancer: where the scientific dispute stands
Underlying the courtroom arguments is a scientific dispute that remains genuinely unresolved in the eyes of the institutions involved, and readers deserve a fair account of both sides rather than a verdict from a news article. In 2015, the International Agency for Research on Cancer, the cancer research arm of the World Health Organization, classified glyphosate as probably carcinogenic to humans, placing it in Group 2A and citing limited evidence in humans for non-Hodgkin lymphoma and stronger evidence in animals. That classification is a hazard assessment: it asks whether a substance is capable of causing cancer under some circumstances, not how likely any one person is to develop cancer from ordinary exposure.
The United States Environmental Protection Agency has taken a different position, repeatedly concluding that glyphosate is not likely to be carcinogenic to humans when used according to its approved labelling, and therefore not requiring a cancer warning on Roundup labels. Regulators in several other countries have reached similar conclusions. The EPA’s position has not gone unchallenged: a federal appeals court in 2022 sent part of the agency’s human-health analysis back for further work, and reporting on the litigation has noted that an updated human-health review is expected in early 2027. Until that review is published and assessed, the regulatory picture remains open, and the contrast between a hazard classification and a risk assessment helps explain why two reputable bodies can look at overlapping evidence and reach different conclusions.
Bayer’s public position aligns with the EPA’s: the company says decades of studies show glyphosate is safe and does not cause cancer when used as directed. Plaintiffs and their supporters align more closely with the IARC classification and with studies they say show an elevated risk of non-Hodgkin lymphoma among the most heavily exposed users. USN does not present either side’s position as settled scientific fact, because the agencies themselves disagree and the research continues. What can be said with confidence is that the legal system and the scientific system are asking different questions: courts ask whether a particular plaintiff has proved, under a particular legal theory, that a defendant should pay, while scientists and regulators ask what the evidence shows about hazard and risk across populations and exposure levels.
What happens next
Several developments will determine what the St. Louis verdict ultimately means. First, the plaintiffs in this case may appeal, and an appellate court would review whether the trial was conducted properly rather than re-deciding the facts from scratch. Second, other post-Durnell trials will go forward on design-defect, fraud and negligence theories, and their outcomes will show whether St. Louis was an outlier or the start of a pattern. Third, the Missouri judge reviewing the proposed 7.25 billion dollar settlement will decide whether that collective resolution moves forward, a decision that could reshape the litigation more broadly than any single trial. Fourth, regulators will continue their own reviews, including the EPA’s expected updated human-health assessment, which could influence both public debate and future legal arguments.
For people who used Roundup and are concerned about their health, the St. Louis verdict changes no medical advice and creates no new legal deadline by itself, but it does underline the importance of seeking independent legal and medical advice rather than drawing conclusions from a single headline. For farmers, gardeners and homeowners who continue to use glyphosate-based products, the EPA-approved label remains the governing instruction for lawful use, including protective equipment and application directions. And for everyone following the case, the clearest lesson of October 30, 2026 is a narrow one: after the Supreme Court closed the failure-to-warn door, the first jury to test what remained chose the defence, and the fight over the remaining theories, the proposed settlement and the science itself is far from over.
Sources
USN reviewed reporting from multiple outlets for this story. Read more from SRN News, Bangkok Post and TradingView.